Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, Calif., March 12, 2020 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:.
Q4 2019 Amphastar Pharmaceuticals Inc Earnings Call
All statements on this conference call that are not historical are forward-looking statements, including, among other things, statements relating to the company's expectations regarding future financial performance, backlog, sales and marketing of its products; market size and growth; the timing of FDA filings or approvals, including the DMF of ANP; the timing of product launches, acquisitions and other materials related to its pipeline of product candidates; its share buyback program and other future events such as the impact of COVID-19 pandemic and related responses of business and government to the epidemic on our operations and personnel and on commercial activity and demand across our business operations and results of operations. Words such as may, might, will, could, would, should, anticipate, predict, potential, continue, expect, intend, plan, project, believe, estimate and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words.
Q1 2020 Amphastar Pharmaceuticals Inc Earnings Call
Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
RANCHO CUCAMONGA, Calif., May 07, 2020 -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March.
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 ...
Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020, after the market closes on Thursday, May 7th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 9246728.
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 12:50 p.m. Eastern Time. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
In 1996 Jack Zhang was appointed CEO of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). This analysis aims first to...
This supplement is for manufacturing the product in the Company’s new manufacturing line at its International Medication Systems facility. It is also helpful for our pipeline projects, which will be produced on the new line. The Company currently has seven Abbreviated New Drug Applications filed with the FDA, which are targeting products with a market size of approximately $1.9 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and nine generic products in development targeting products with a market size of approximately $12 billion.
Mr. Jason B. Shandell has stepped down as President, General Counsel, and member of the Board of Directors, effective April 10, 2020. Mr. Shandell and the Company have mutually agreed that now is the right time to transition and to consolidate the Company’s management structure. The Company thanks Mr. Shandell for his service over the past twelve years and wishes him success in his future endeavors.
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress
Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its fourth quarter of 2019 ended December 31, 2019, after the market closes on Thursday, March 12th, 2019, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 4863509.
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
Amphastar’s newly approved drug product was determined by the FDA to be therapeutically equivalent to Adrenalin® (Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial) distributed in the United States by Par Pharmaceutical, Inc. Epinephrine Injection Multiple Dose Vial is for intramuscular, subcutaneous, and intravenous use, and is indicated for emergency treatment of allergic reactions (Type 1), including anaphylaxis, and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Additionally, the FDA granted 180 day exclusivity to Amphastar as the first generic filer.
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.